Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Insomnia, Insomnia Disorder, Chronic Insomnia, Chronic Insomnia Disorder
Interventions
Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg, Diphenhydramine, 25 mg, Diphenhydramine, 50 mg, Doxepin, 3 mg, Doxepin, 6 mg, Trazodone, 50 mg, Trazodone, 100 mg, Placebo, Zolpidem, 5 mg, Zolpidem, 10 mg
Other · Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Oral Mucositis Pain
Interventions
doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
350
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 221 more
Completed Phase 4 Interventional Results available

The Treatment of Insomnia in Patients With HIV Disease

NCT00465972
Conditions
HIV Infections, Insomnia
Interventions
Doxepin, Temazepam, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Sleep Quality Post-TKA, Postoperative Knee Function, Quality of Life After Primary TKA
Interventions
Doxepin 6 mg, Ramelteon 8 mg, Placebo Tablets
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Healthy
Interventions
Silenor 6 mg, zolpidem 10 mg, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Novi, Michigan
Not listed Phase 3 Interventional

Using Doxepin for Urticaria

NCT05115136
Conditions
Urticaria
Interventions
Doxepin, Diphenhydramine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Syracuse, New York